Publications by authors named "H A Wotherspoon"
Article Synopsis
- Regulatory applications for cell therapies face more objections than traditional drugs, primarily due to inadequacies in preclinical evidence like study design and animal model selection, causing delays in approvals.
- A scoping review of 1215 documents from major regulatory agencies identified 182 relevant papers, highlighting the critical role of understanding the mechanism of action in preclinical studies.
- While most guidelines stressed using clinically relevant preclinical models and intervention parameters, there were fewer specific recommendations on disease models and proper study designs like randomization and blinding.
Background And Aims: Currently there is no protocol in the west of Scotland for the investigation of a patient with a lymph node in the neck which might contain lymphoma. The aim of this audit was to examine the current management of these patients.
Methods: Data were collected on 112 patients diagnosed as having lymphoma from a neck node biopsy within a 12 month period from 1st November 2004 to 31st October 2005.
Background And Aim: Waiting times for patients with lymphoma have been reported across the United Kingdom since 2005. Lymphoma however, is not a single disease but a wide spectrum of lymphoid tumours that range from the most malignant to the most indolent, from highly curable to incurable. We now question the value of the current system that reports lymphoma waiting time on a quarterly basis and makes no allowance for the different types of lymphoma.
View Article and Find Full Text PDFBackground: Recent reports based on registry data have shown that survival after surgery for colorectal cancer is improving in the UK. It is not clear whether these improvements are due to earlier presentation or more effective treatment.
Methods: Outcome for 645 patients with colorectal cancer admitted to Glasgow Royal Infirmary between 1974 and 1979 was compared with that for 354 patients admitted between 1991 and 1994.